Hyloris Pharmaceuticals SA (FRA:52U)

Market Cap	110.32M -28.9%
Revenue (ttm)	9.83M +16.2%
Net Income	-4.65M
EPS	-0.17
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	90
Open	3.940
Previous Close	3.760
Day's Range	3.940 - 3.940
52-Week Range	3.500 - 8.140
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Mar 25, 2027

About Hyloris Pharmaceuticals

Hyloris Pharmaceuticals SA operates as a specialty pharmaceutical company in Belgium, the United States, Europe, the Middle East, Africa, and Asia-Pacific. The company offers Maxigesic IV for the treatment of post-operative pain; Podofilox gel, a topical antimycotic drug for external genital and perianal warts; Sotalol IV, an intravenous formulation of sotalol for the treatment of atrial fibrillation, and life-threatening ventricular arrhythmias; and Valacyclovir oral suspension for the treatment of herpes virus infections. It also provides Ato...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2012
• Employees: 54
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 52U

Financial Performance

In 2025, Hyloris Pharmaceuticals's revenue was 7.94 million, a decrease of -18.66% compared to the previous year's 9.76 million. Losses were -6.33 million, -0.13% less than in 2024.

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Oct 26, 2026

Data Sources Report a data error